In today’s recent session, 0.55 million shares of the Travere Therapeutics Inc (NASDAQ:TVTX) have been traded, and its beta is 0.73. Most recently the company’s share price was $14.40, and it changed around -$0.83 or -5.45% from the last close, which brings the market valuation of the company to $1.10B. TVTX at last check was trading at a discount to its 52-week high of $15.46, offering almost -7.36% off that amount. The share price’s 52-week low was $5.12, which indicates that the recent value has risen by an impressive 64.44% since then. We note from Travere Therapeutics Inc’s average daily trading volume that its 10-day average is 2.16 million shares, with the 3-month average coming to 1.55 million.
Travere Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.47. If we narrow it down even further, the data shows that 0 out of 16 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 5 recommended TVTX as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Travere Therapeutics Inc (NASDAQ:TVTX) trade information
Instantly TVTX has been showing red trend so far today with a performance of -5.45% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 15.46 on recent trading dayincreased the stock’s daily price by 6.86%. The company’s shares are currently up 60.18% year-to-date, but still up 2.93% over the last five days. On the other hand, Travere Therapeutics Inc (NASDAQ:TVTX) is 31.15% up in the 30-day period. We can see from the shorts that 8.66 million shares have been sold at a short interest cover period of 5.94 day(s).
The consensus price target as assigned by Wall Street analysts is $18, which translates to bulls needing to increase their stock price by 20.0% from its current value. Analyst projections state that TVTX is forecast to be at a low of $12 and a high of $28.
Travere Therapeutics Inc (TVTX) estimates and forecasts
Travere Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 106.90 percent over the past six months and at a 22.09% annual growth rate that is well above the industry average of 17.60%. Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -12.34%.
Travere Therapeutics Inc (NASDAQ:TVTX)’s Major holders
ARMISTICE CAPITAL, LLC, with 9.6774% or 7.5 million shares worth $61.65 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
